SBRT or TACE for Advanced HCC
Randomized study of stereotactic body radiation therapy (SBRT) versus transarterial chemoembolization (TACE) in locally advanced hepatocellular carcinoma.
Hepatocellular Carcinoma
DRUG: DEB|RADIATION: SBRT
Progression (total of local, intra- and extrahepatic), Modified RECIST, 1 year
Response, Modified RESIST, 3 months|Local control of treated tumor, Modified RECIST, 1 year|Intrahepatic failure, Intrahepatic failure (more than 1 cm away), 1 year|Extrahepatic failure, Modified RECIST, 1 year|Overall survival, Overall survival, 1 year|Treatment related toxicity, Tox CTC Ver 4.0, 1 year|Cost-benefit, $ spend on hospitalization and treatment of complications after the treatment, 1 year
Randomized study of stereotactic body radiation therapy (SBRT) versus transarterial chemoembolization (TACE) in locally advanced hepatocellular carcinoma.